hematological malignancies
Conditions
Interventions
Gold Standard:pathology or long-term clinical follow-up
Index test:Al18F-NOTA-Pentixafor and18F-FDG PET/CT imaging
Sponsors
Sichuan cancer hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Informed consent signed by the patient or his legal representative; (2) Patients who came to our hospital on October 1, 2023 and were clinically judged or diagnosed as malignant tumors were selected, with complete clinical and follow-up data.
Exclusion criteria
Exclusion criteria: (1) People who have a history of allergies to similar drugs (drugs with similar chemical or biological components to CXCR4), allergic constitution or are currently suffering from allergic diseases; (2) People who are in clinical trials of other drugs, or who have participated in clinical trials of any drugs (excluding vitamins and minerals); (3) have other clinical problems that are difficult to control (such as HIV, hepatitis C virus infection or active hepatitis B, or other serious chronic infections and serious mental, neurological, cardiovascular, respiratory and other diseases); (4) Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy test); (5) Patients whose physical condition is not suitable for radiological examination; (6) Those who researchers think need to be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity, SE;Specificity, SP;Accuracy;Maximum standardized uptake value,SUVmax;Mean standardized uptake value,SUVmean; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive predicative value,PPV;Negative predicative value,NPV; | — |
Countries
China
Contacts
Public ContactYing Kou
Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China
Outcome results
None listed